KR101423229B1 - 항박테리아제로서의 퀴놀린 유도체 - Google Patents

항박테리아제로서의 퀴놀린 유도체 Download PDF

Info

Publication number
KR101423229B1
KR101423229B1 KR1020087002248A KR20087002248A KR101423229B1 KR 101423229 B1 KR101423229 B1 KR 101423229B1 KR 1020087002248 A KR1020087002248 A KR 1020087002248A KR 20087002248 A KR20087002248 A KR 20087002248A KR 101423229 B1 KR101423229 B1 KR 101423229B1
Authority
KR
South Korea
Prior art keywords
alkyl
alkyloxy
compound
hydrogen
halo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020087002248A
Other languages
English (en)
Korean (ko)
Other versions
KR20080028460A (ko
Inventor
코엔라드 요제프 로데비이크 마르셀 안드리스
아닐 코울
제롬 에밀 조리 귈레몽
마갈리 마델렌 시몬 모테
Original Assignee
얀센 파마슈티카 엔.브이.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 얀센 파마슈티카 엔.브이. filed Critical 얀센 파마슈티카 엔.브이.
Publication of KR20080028460A publication Critical patent/KR20080028460A/ko
Application granted granted Critical
Publication of KR101423229B1 publication Critical patent/KR101423229B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/36—Sulfur atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020087002248A 2005-06-28 2006-06-26 항박테리아제로서의 퀴놀린 유도체 Expired - Fee Related KR101423229B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP05105769 2005-06-28
EP05105769.3 2005-06-28
PCT/EP2006/063556 WO2007000436A1 (en) 2005-06-28 2006-06-26 Quinoline derivatives as antibacterial agents

Publications (2)

Publication Number Publication Date
KR20080028460A KR20080028460A (ko) 2008-03-31
KR101423229B1 true KR101423229B1 (ko) 2014-07-25

Family

ID=35445742

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020087002248A Expired - Fee Related KR101423229B1 (ko) 2005-06-28 2006-06-26 항박테리아제로서의 퀴놀린 유도체

Country Status (33)

Country Link
US (2) US20100204270A1 (enExample)
EP (1) EP1898910B1 (enExample)
JP (1) JP5193859B2 (enExample)
KR (1) KR101423229B1 (enExample)
CN (1) CN101252928B (enExample)
AP (1) AP2733A (enExample)
AR (1) AR057654A1 (enExample)
AU (1) AU2006263884B2 (enExample)
BR (1) BRPI0612534B8 (enExample)
CA (1) CA2612623C (enExample)
CY (1) CY1118515T1 (enExample)
DK (1) DK1898910T3 (enExample)
EA (1) EA014163B1 (enExample)
ES (1) ES2606772T3 (enExample)
HR (1) HRP20161704T1 (enExample)
HU (1) HUE031268T2 (enExample)
IL (1) IL188394A (enExample)
JO (1) JO3270B1 (enExample)
LT (1) LT1898910T (enExample)
ME (1) ME02690B (enExample)
MX (1) MX2008000082A (enExample)
MY (1) MY151030A (enExample)
NO (1) NO341283B1 (enExample)
NZ (1) NZ564339A (enExample)
PL (1) PL1898910T3 (enExample)
PT (1) PT1898910T (enExample)
RS (1) RS55408B1 (enExample)
SG (1) SG166799A1 (enExample)
SI (1) SI1898910T1 (enExample)
TW (1) TWI392494B (enExample)
UA (1) UA91549C2 (enExample)
WO (1) WO2007000436A1 (enExample)
ZA (1) ZA200711149B (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9790186B2 (en) 2009-07-21 2017-10-17 Trustees Of Dartmouth College Composition and method for prevention, mitigation or treatment of an enteropathogenic bacterial infection
CN104254527B (zh) 2012-04-27 2017-05-31 詹森药业有限公司 抗菌的喹啉衍生物
AU2013254670B2 (en) 2012-04-27 2017-03-30 Janssen Pharmaceutica Nv Antibacterial quinoline derivatives
CN105037497B (zh) * 2015-03-27 2018-06-26 中牧实业股份有限公司 一种恩拉霉素的提纯方法
WO2017035288A1 (en) * 2015-08-27 2017-03-02 Trustees Of Dartmouth College Composition and method for prevention, mitigation or treatment of an enteropathogenic bacterial infection

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000034265A2 (en) * 1998-12-11 2000-06-15 Sepracor, Inc. Quinoline-indole antimicrobial agents
WO2004011436A1 (en) * 2002-07-25 2004-02-05 Janssen Pharmaceutica N.V. Quinoline derivatives and their use as mycobacterial inhibitors

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19937116A1 (de) * 1999-08-06 2001-02-08 Bayer Ag Moxifloxacin Kochsalzformulierung
EP1753427B1 (en) * 2004-05-28 2008-04-02 Janssen Pharmaceutica N.V. Use of substituted quinoline derivatives for the treatment of drug resistant mycobacterial diseases
EE05394B1 (et) * 2004-12-24 2011-04-15 Janssen Pharmaceutica N.V. Kinoliinihendid kasutamiseks latentse tuberkuloosi ravis

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000034265A2 (en) * 1998-12-11 2000-06-15 Sepracor, Inc. Quinoline-indole antimicrobial agents
WO2004011436A1 (en) * 2002-07-25 2004-02-05 Janssen Pharmaceutica N.V. Quinoline derivatives and their use as mycobacterial inhibitors

Also Published As

Publication number Publication date
ME02690B (me) 2017-10-20
EA200800152A1 (ru) 2008-06-30
CY1118515T1 (el) 2017-07-12
IL188394A (en) 2012-09-24
CA2612623A1 (en) 2007-01-04
JO3270B1 (ar) 2018-09-16
NZ564339A (en) 2011-02-25
AU2006263884A1 (en) 2007-01-04
ES2606772T3 (es) 2017-03-27
PT1898910T (pt) 2016-11-16
BRPI0612534A2 (pt) 2010-11-23
SI1898910T1 (sl) 2017-01-31
NO20080481L (no) 2008-02-29
AP2733A (en) 2013-09-30
RS55408B1 (sr) 2017-04-28
MY151030A (en) 2014-03-31
AR057654A1 (es) 2007-12-12
JP2008546825A (ja) 2008-12-25
AU2006263884B2 (en) 2013-01-10
TW200738237A (en) 2007-10-16
HUE031268T2 (en) 2017-06-28
IL188394A0 (en) 2008-08-07
JP5193859B2 (ja) 2013-05-08
CN101252928A (zh) 2008-08-27
BRPI0612534B8 (pt) 2021-05-25
EP1898910B1 (en) 2016-09-28
ZA200711149B (en) 2009-06-24
SG166799A1 (en) 2010-12-29
NO341283B1 (no) 2017-10-02
PL1898910T3 (pl) 2017-03-31
BRPI0612534B1 (pt) 2020-04-22
HRP20161704T1 (hr) 2017-02-10
DK1898910T3 (en) 2017-01-09
US20100204270A1 (en) 2010-08-12
LT1898910T (lt) 2017-01-10
MX2008000082A (es) 2008-03-24
BRPI0612534A8 (pt) 2017-12-26
HK1120734A1 (en) 2009-04-09
EA014163B1 (ru) 2010-10-29
UA91549C2 (ru) 2010-08-10
CA2612623C (en) 2016-09-27
EP1898910A1 (en) 2008-03-19
WO2007000436A1 (en) 2007-01-04
US20130030017A1 (en) 2013-01-31
KR20080028460A (ko) 2008-03-31
TWI392494B (zh) 2013-04-11
CN101252928B (zh) 2012-05-23

Similar Documents

Publication Publication Date Title
KR101490222B1 (ko) 항균성 퀴놀린 유도체
KR101337237B1 (ko) 항균제로서의 퀴놀린 유도체
KR101413997B1 (ko) 항균제로서의 퀴놀린 유도체
CN101232884B (zh) 作为抗菌剂的喹啉衍生物
KR101526175B1 (ko) 항박테리아 퀴놀린 유도체
KR101574642B1 (ko) 항균성 퀴놀린 유도체
KR101490221B1 (ko) 항박테리아 퀴놀린 유도체
KR101329587B1 (ko) 항균제로서의 퀴놀린 유도체
KR101413094B1 (ko) 항박테리아제로서의 퀴놀린 유도체
KR101423229B1 (ko) 항박테리아제로서의 퀴놀린 유도체
KR101329585B1 (ko) 항균제로서 퀴놀린 유도체
KR101318181B1 (ko) 항균제로서의 퀴놀린 유도체
HK1124232B (en) Quinoline derivatives as antibacterial agents
HK1122730B (en) Quinoline derivatives as antibacterial agents
HK1120734B (en) Quinoline derivatives as antibacterial agents

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

FPAY Annual fee payment

Payment date: 20170616

Year of fee payment: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

FPAY Annual fee payment

Payment date: 20190617

Year of fee payment: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 8

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 9

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20230719

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20230719